Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469465 · ClinicalTrials.gov registry record · Phase 3
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT04469465 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT04469465, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.
Interventions
- DRUG Placebo
- DRUG Danicopan
- DRUG C5 Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04469465
The ClinicalTrials.gov registry entry for NCT04469465 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04469465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04469465 about?
NCT04469465 is a clinical study titled "Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)". The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.
What is the current status of trial NCT04469465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2020-12-16. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT04469465?
The interventions under investigation include: Placebo (DRUG), Danicopan (DRUG), C5 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT04469465?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.